AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7480274
Drug: Betamethasone 6
RxNorm normalized name: betamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 6 mg IM preoperatively
Trial: 2381618
Drug: 1.6% terconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6% terconazole cream
Trial: 7030835
Drug: CDCA (12‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA (12‐15 mg/kg/day)
Trial: 7030835
Drug: UDCA (5‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (5‐6 mg/kg/day)
Trial: 7030835
Drug: UDCA (10‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (10‐12 mg/kg/day)
Trial: 28342637
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus short-term prednisone (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18; prednisone 0.5 or 1.0 mg/kg per day tapered over 3 or 6 months)
Trial: 28342637
Drug: Prednisone alone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone alone (1.0 or 1.5 mg/kg per day tapered over 12 or 18 months)
Trial: 19119169
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic gel (20 percent benzocaine gel) applied for 2 minutes
Trial: 15155717
Drug: 6% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% CHO solution before and during training and 20% solution post-exercise (H-CHO trial)
Trial: 15155717
Drug: 2% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHO solution before and during training and 2% solution post-exercise (L-CHO trial)
Trial: 15155717
Drug: L-CHO trial
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-CHO trial
Trial: 11439734
Drug: Rofecoxib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (5 to 50 mg)
Trial: 9603669
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied 1% beta‐LHA formulation
Trial: 3403064
Drug: Beta-carotene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (180 mg/week)
Trial: 3403064
Drug: Beta-carotene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (180 mg/week) plus vitamin A (100,000 IU/week)
Trial: 26613819
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg misoprostol with 10 units of oxytocin
Trial: 16167707
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Trial: 16167707
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Trial: 3219882
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pinaverium bromide intravenously
Trial: 3219882
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg pinaverium bromide intravenously
Trial: 23775505
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at steady-state effect-site concentrations of 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml
Trial: 23775505
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three surrogate parameters (pupil diameter, light reflex amplitude, and tracking performance)
Trial: 21569011
Drug: Context therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Context therapy
Trial: 16800900
Drug: Whole-brain radiotherapy
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiotherapy plus chemotherapy
Trial: 11919130
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x NPH daily
Trial: 10503820
Drug: Long-term acid
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term acid inhibition therapy
Trial: 10503820
Drug: Long-term acid-inhibitory
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term acid-inhibitory therapy for an average of three years
Trial: 2260008
Drug: Hypoxyradiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxyradiotherapy with a mixture of nitrogen and oxygen containing 8.0 to 8.5% O2, increased external irradiation doses by 40%
Trial: 25166480
Drug: Ecopipam (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam (50 to 100 mg/d as needed)
Trial: 22940562
Drug: Prescribed opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed opioid dose
Trial: 22940562
Drug: Patient-reported opioid
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported opioid dose
Trial: 17181890
Drug: Dairy group
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy group (DG: n 39) receiving approximately 1200 mg calcium/d and 7.5 microg vitamin D3/d through fortified dairy products
Trial: 17181890
Drug: Calcium-supplemented group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-supplemented group (CaG: n 26) provided with a calcium supplement of 600 mg/d
Trial: 14523483
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with stent implantation and GP IIb/IIIa receptor inhibitors in patients with NSTEACS (group A)
Trial: 10813102
Drug: Lovelle (desogestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovelle (desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg)
Trial: 10813102
Drug: Valette (dienogest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valette (dienogest 2.0 mg plus ethinyl estradiol 0.03 mg)
Trial: 8785183
Drug: Oxymetholone monotherapy
RxNorm normalized name: Oxymetholone
DrugBank: Oxymetholone (DB06412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetholone monotherapy
Trial: 8785183
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Oxymetholone monotherapy and Oxymetholone plus ketotifen)
Trial: 7091039
Drug: EG AA
RxNorm normalized name: Ethinyl Estradiol and Norethindrone Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG AA group, 3 eggs + 2 g ascorbic acid
Trial: 7091039
Drug: AA group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA group, 2 g ascorbic acid
Trial: 31912490
Drug: Community-based couple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based couple therapy
Trial: 27669288
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (6000 IU daily for 12 weeks)
Trial: 27669288
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement (for those with vitamin D status over 75 nmol/L)
Trial: 24731234
Drug: Group care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group care (GC) treatment as usual (TAU)
Trial: 21115589
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (5‐methyltetrahydrofolate 560 μg, vitamin B‐6 3 mg, vitamin B‐12 20 μg)
Trial: 21115589
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 fatty acids (600 mg of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1)
Trial: 18784373
Drug: Tocilizumab (anti-IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (anti-IL-6 receptor antibody)
Trial: 16005273
Drug: Oral salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salmon calcitonin (sCT) 1.0 mg
Trial: 16005273
Drug: Oral salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salmon calcitonin (sCT) (0.15, 0.4, 1.0, or 2.5 mg)
Trial: 10095141
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 50% sucrose solution
Trial: 10095141
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml sterile water (placebo)
Trial: 1317687
Drug: Lisinopril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (mean dose 35 mg qd)
Trial: 1317687
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean dose 54 mg bid)
Trial: 23157083
Drug: Local instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local instillation of 0.75% ropivacaine (20 ml)
Trial: 19592206
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (20,000 IU, 10 daily doses starting from the day of trauma)
Trial: 19017587
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of daily rifampin therapy
Trial: 19017587
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of daily isoniazid therapy
Trial: 15747247
Drug: 1x10(5) TCID(50)
RxNorm normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x10(5) TCID(50) bPIV3 vaccine
Trial: 15747247
Drug: 1x10(6) TCID(50)
RxNorm normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x10(6) TCID(50) bPIV3 vaccine
Trial: 12451727
Drug: Ribavirin 1200
RxNorm normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 1200 mg daily
Trial: 10600085
Drug: Multidisciplinary antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary antimicrobial treatment team intervention
Trial: 29305400
Drug: Escalated drug
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalated drug therapy in amio-refractory patients
Trial: 29305400
Drug: Escalated drug
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalated drug therapy in sotalol-refractory patients
Trial: 28083797
Drug: Oral fludrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludrocortisone
Trial: 28083797
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral fludrocortisone and intravenous hydrocortisone
Trial: 22245630
Drug: Saracatinib 50
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 50 mg/day
Trial: 22245630
Drug: Saracatinib 125
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 125 mg/day
Trial: 22245630
Drug: Saracatinib 175
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 175 mg/day
Trial: 15947502
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 2% with intracameral lidocaine 1%
Trial: 15947502
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical anesthesia (bupivacaine 0.5, oxybuprocaine, and diclofenac eyedrops) with intracameral lidocaine 1%
Trial: 12889589
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral broad spectrum Ampicillin/Amoxicillin and Erythromycin therapy during conservative management of pPROM before 32 weeks' gestation
Trial: 8997659
Drug: Small particle
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small particle size tetracycline in gel
Trial: 8997659
Drug: Large particle
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large particle size tetracycline in gel
Trial: 1631985
Drug: Simple CPAP
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple CPAP with a 10 l latex balloon reservoir
Trial: 29422181
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music intervention (four consecutive weekly 1-hour music classes)
Trial: 26787792
Drug: Sugammadex (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (0.25, 0.5, 0.75, 1.0, or 1.25 mg kg(‐1) i.v.)
Trial: 26787792
Drug: Neostigmine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (10, 25, 40, 55, or 70 µg kg(‐1) i.v.)
Trial: 20816042
Drug: Armodafinil 50
RxNorm normalized name: armodafinil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 50 mg
Trial: 17432112
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or statins
Trial: 16087943
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (12 doses) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Trial: 24647391
Drug: Aromatic amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic amino acid (AAA) supplementation (330 mg · kg(‐1) · d(‐1))
Trial: 22334767
Drug: Individualized training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized training program designed to improve activity of daily living (ADL) and physical capacity, lasting for 3 months.
Trial: 8665880
Drug: Midazolam followed
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam followed by vecuronium 0.1 mg kg‐1
Trial: 8665880
Drug: Midazolam followed
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam followed by atracurium 0.5 mg kg‐1
Trial: 2667526
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of luffa operculata D4, kalium bicromicum D4 and cinnabaris D3
Trial: 2667526
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of kalium bicromicum D4 and cinnabaris D3
Trial: 1002948
Drug: Methylphenidate combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate combined with behavior therapy
Trial: 30830727
Drug: pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate 0.2 mg/d
Trial: 30830727
Drug: pemafibrate 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemafibrate 0.4 mg/d
Trial: 30830727
Drug: placebo/pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/pemafibrate 0.2 mg/d
Trial: 25336333
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m² daily for 5 days
Trial: 25336333
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m² daily for 5 days plus oral valproic acid 50 mg/kg daily for 7 days
Trial: 22451457
Drug: No compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No compression treatment
Trial: 15277160
Drug: Cactus pear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cactus pear fruit (250 g fresh fruit pulp)
Trial: 15277160
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (75 mg twice daily)
Trial: 3318445
Drug: Ibuprofen 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 1,200 mg
Trial: 28985142
Drug: Sour cherries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sour cherries (500 g daily for 30 days)
Trial: 28985142
Drug: Apples (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apples (500 g daily for 30 days)
Trial: 26120851
Drug: Didactic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didactic injection risk intervention
Trial: 20659602
Drug: Probiotic prophylaxis
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic prophylaxis (1 capsule of Probaclac Vaginal containing 8 billion CFUs of Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus)
Trial: 18834368
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention (monthly 1-hour education programme)
Trial: 15827569
Drug: Citalopram (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (7.5 mg intravenously)
Trial: 11978284
Drug: Preoperative recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative recombinant human erythropoietin therapy
Trial: 11978284
Drug: No erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No erythropoietin therapy (Control)
Trial: 8626885
Drug: Nefazodone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (200 mg every 12 hours) and Propranolol (40 mg every 12 hours)
Trial: 6448025
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin hydrochloride hydrate applied twice daily for eight weeks
Trial: 6448025
Drug: Vehicle alone
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle alone applied twice daily for eight weeks
Trial: 6448025
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin hydrochloride hydrate
Trial: 28261906
Drug: Two-piece implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-piece implant with a progressive platform widening and a platform switching connection (SP)
Trial: 28261906
Drug: One-piece implant
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-piece implant with a machined collar (TG)
Trial: 19752419
Drug: 1‐mg intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg intravitreal triamcinolone
Trial: 19752419
Drug: 4‐mg intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐mg intravitreal triamcinolone
Trial: 19752419
Drug: 1‐mg vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg vs 4‐mg intravitreal triamcinolone
Trial: 19752419
Drug: Observation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation and 1‐mg intravitreal triamcinolone
Trial: 15537905
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of anti-interleukin-12 per kilogram
Trial: 7826790
Drug: Midwife top‐up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midwife top‐up doses of 0.25% bupivacaine 10 ml
Trial: 7826790
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.125% bupivacaine 10 ml h‐1
Trial: 7826790
Drug: Patient-controlled extradural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled extradural analgesia (PCEA) with self‐administered 3‐ml bolus doses of 0.25% bupivacaine
Trial: 29798443
Drug: Ginkgo Leaves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Leaves Soft-gel Capsule and Qiangli Dingxuan tablets (Drug group)
Trial: 22298804
Drug: Cotreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotreatment with pegvisomant (15‐30 mg twice a week) and SA (half the usual dosage)
Trial: 22298804
Drug: SA monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA monotherapy
Trial: 19356426
Drug: Systematic heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic heart rate control (oral and intravenous beta-blockade for a target heart rate ≤60 beats/min) in single-source CT
Trial: 15161787
Drug: metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (1,500 mg/day)
Trial: 11578882
Drug: Fentanyl (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (administered according to anesthesiologists' usual practice)
Trial: 7816293
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0.1 ml of the vehicle